Frederick Hiller Ii Institution-verified

Grants & Funding

• A 52-week, Double-Blind, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Effect of Roflumilast 500 µg on Exacerbation Rate in Subj Forest Research Institute Principal Investigator
• Protocol 3000-0409: Phase III, Randomized, Open-Label, Study of Aquavan Injection vs Midazolam HCL for Sedation in Patients Undergoing Flexible Bronch PPD Development, LP Principal Investigator
• a comparative study of LAS 34273 versus placebo in the treatment of stable, moderate to severe COPD, also known as ACCLAIM II Almirall Prodesfarma, S.A. Principal Investigator
• Protocol 3000-0409: Phase III, Randomized, Open-Label, Study of Aquavan Injection vs Midazolam HCL for Sedation in Patients Undergoing Flexible Bronch PPD Development, LP Principal Investigator
• A randomized, multicenter, placebo-controlled parallel group study of four months duration per subject to evaluate the safety and efficacy of treatmen NOVARTIS Pharmaceuticals Corporation Principal Investigator
• Effect of roflumilast on exacerbation rate in patients with COPD. A 52 week, double-blind study with 500 mcg roflumilast once daily versus placebo. Altana Pharma Principal Investigator
• Protocol No. NA17098, “A Multi-Center, Randomized, Double-Blind, Placebo, Controlled Phase 2a Dose-Response Study of the Safety and Tolerability of Tw Hoffmann-La Roche, Inc. Principal Investigator
• A randomized, multicenter, placebo-controlled parallel group study of four months duration per subject to evaluate the safety and efficacy of treatmen NOVARTIS Pharmaceuticals Corporation Principal Investigator

Similar Researchers

Based on overlapping research topics